FIELD: biotechnology.
SUBSTANCE: described is a compound for use in therapy, which is a polypeptide having a half-life expressed as t1/2-beta in a human for at least 3 days. Polypeptide contains a single immunoglobulin variable domain (ISV) at its C-terminal, wherein the said ISV is either VHH optimized by the VHH sequence, humanised VHH or camellated VH or is ISV, which is based on the VH (one) domain antibody based on VH dAb™ or based on the VH microbody. ISV has a C-terminal VTVSS(X)n sequence, where n = 1, 2 or 3, in which each X = Ala or Gly; or n = 1, 2 or 3, in which each X = Ala; or n = 1, 2 or 3, in which each X = Gly; or n = 2 or 3, wherein at least one X = Ala or Gly; or n = 2 or 3, wherein all except one X = Ala or Gly. Polypeptide also contains a peptide which binds serum albumin or a serum albumin binding domain.
EFFECT: invention enables solving the problem of protein interference in ADA-analysis.
22 cl, 9 dwg, 12 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS FOR PREDICTION, DETECTION AND REDUCTION OF NON-SPECIFIC INTERFERENCE OF PROTEINS IN METHODS OF ANALYSIS USING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULINS | 2012 |
|
RU2822520C2 |
METHODS FOR PREDICTION, DETECTION AND REDUCTION OF NON-SPECIFIC PROTEIN INTERFERENCE IN ANALYSIS METHODS USING SINGLE VARIABLE DOMAIN OF IMMUNOGLOBULINS | 2012 |
|
RU2798971C2 |
IMPROVED PHARMACOKINETIC ASSAYS FOR SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS | 2017 |
|
RU2765809C2 |
IMMUNOGLOBULINS BINDING AGGRECAN | 2018 |
|
RU2771818C2 |
IMPROVED TNF-BINDING AGENTS | 2016 |
|
RU2774823C2 |
IMPROVED VARIABLE DOMAINS OF IMMUNOGLOBULINS | 2015 |
|
RU2746738C2 |
IMPROVED NANO-BODIES AGAINST HUMAN SERUM ALBUMIN | 2012 |
|
RU2634381C2 |
ADAMTS-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2781182C2 |
TNF-α BINDING POLYPEPTIDE AND METHOD FOR TREATMENT OF TNF-α RELATED DISEASES | 2017 |
|
RU2794974C2 |
IMPROVED SUBSTANCES BINDING TO SERUM ALBUMIN | 2018 |
|
RU2789495C2 |
Authors
Dates
2019-09-18—Published
2012-06-25—Filed